Cadence Capital Management’s Integra LifeSciences IART Stock Holding History

Cadence Capital Management’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-22,640	Closed	-$767K	–	650
2015 Q4	$767K	Buy	+22,640	New	+$708K	0.05%	378

Other funds holding IART

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Cadence Capital Management's IART Position: Q1 2016 in Review

Cadence Capital Management sold out of Integra LifeSciences (IART) in Q1 2016, closing a stake of 22,640 shares — an estimated $767K sold.

Cadence Capital Management first reported a position in IART in Q4 2015 and held it in 1 quarter. The position peaked at $767K in Q4 2015. 194 funds tracked by Wall St. Rank hold IART as of Q1 2016.

Cadence Capital Management reported no remaining Integra LifeSciences position as of Q1 2016 after selling out during the quarter.
Cadence Capital Management sold 22,640 Integra LifeSciences shares in Q1 2016, an estimated $767K.
Cadence Capital Management first reported a position in Integra LifeSciences in Q4 2015 and held it in 1 quarter.
Cadence Capital Management's Integra LifeSciences position peaked at $767K in Q4 2015.
194 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2016.

Based on Cadence Capital Management's 13F filing for Q1 2016, filed 2 May 2016.